Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
BuTrans Buprenorphine transdermal patch Pain, moderate intensity persistent pain Do not list Complete
Byetta Exenatide Diabetes mellitus, type 2 Do not list Complete
Bylvay odevixibat Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Complete
Bystolic Nebivolol Hypertension Do not list at the submitted price Complete
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete
Cabometyx cabozantinib Differentiated thyroid carcinoma Reimburse with clinical criteria and/or conditions Complete
Cabometyx Cabozantinib Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Complete
Cabometyx cabozantinib Advanced or metastatic renal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Cabometyx Cabozantinib HCC Reimburse with clinical criteria and/or conditions Complete